The drug that will make chemotherapy obsolete

New anti-cancer targeted agent is expected to become an effective tool in the treatment of breast and ovarian cancer patients.

July 22, 2010 12:05
1 minute read.
Iluz (left) and Abuhatzeira, with Prof. Dan Aravot

Artificial heart patients 311. (photo credit: Eli Dadon )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

A new medicine in development is expected to make one of the most dreaded treatments in the fight against cancer - irrelevant. A new study conducted in both Europe and the US reports that a newly developed agent, Olaparib, will help attack breast and ovarian tumors effectively without subjecting patients to chemotherapy.

The researchers explain that Olaparib inhibits a certain protein that is involved in the reproduction of cancerous cells. The inhibition of this protein, in a tumor cell that already lacks a functional BRCA gene, will induce cell death.

Be the first to know - Join our Facebook page.

The study was undertaken in 16 centers in Australia, Germany, Spain, Sweden, the UK and the US, and included women aged 18 years or more who suffered from recurrent, advanced breast cancer and had been given a few previous chemotherapy regimens.

The patients were assigned to one of two groups – 27 women were given 400 mg oral Olaparib twice daily and the other 27 women were given 100 mg oral Olaparib twice daily. The higher dose showed a better anti-tumorous activity, with an objective response rate of 41%, compared with an objective response rate of 22% in the lower dose group. Adverse events were mainly at low grades, mostly in the higher dose group, and included fatigue, nausea, vomiting and anemia.

More clinical trials are necessary before Olaparib and other PARP inhibitors may be used in practice, but these recent studies give new hope for the future.

To read more about cancer case studies and medical opinions, go to:

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia